NCT07808866 Multi-Agent Collaborative ADR Prediction With Human-Machine Decision Comparison
| NCT ID | NCT07808866 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Third Hospital |
| Condition | Adverse Drug Reactions |
| Study Type | OBSERVATIONAL |
| Enrollment | 20,000 participants |
| Start Date | 2026-06-19 |
| Primary Completion | 2027-06-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20,000 participants in total. It began in 2026-06-19 with a primary completion date of 2027-06-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study develops a multi-agent collaborative prediction model to forecast adverse drug reactions using real-world clinical medical records. It validates model performance via evidence-based data and compares decision outputs between the AI model and clinical physicians, aiming to improve early identification of drug adverse events. Only de-identified historical medical data will be analyzed; no new clinical interventions will be conducted, with no additional risks to participants.
Eligibility Criteria
Inclusion Criteria: * Cases shall involve drug categories including anti-infectives, cardiovascular agents, anti-tumor drugs, central nervous system drugs, digestive system drugs, etc. Each case must contain at least one definite adverse drug reaction (ADR) event, with complete supporting documentation (medical history, medication history, ADR occurrence process, and clinical outcome). Exclusion Criteria: * Cases with incomplete supporting documentation lacking medical history, medication history, ADR occurrence process or clinical outcome. * Cases only with suspected or possible ADRs without definite clinical confirmation.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07808866 clinical trial?
This trial is open to participants of all sexes, studying Adverse Drug Reactions. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07808866 currently recruiting?
Yes, NCT07808866 is actively recruiting participants. Contact the research team at zhangwl2012@126.com for enrollment information.
Where is the NCT07808866 trial being conducted?
This trial is being conducted at Beijing, China, Beijing, China.
Who is sponsoring the NCT07808866 clinical trial?
NCT07808866 is sponsored by Peking University Third Hospital. The trial plans to enroll 20,000 participants.